Report of Foreign Issuer (6-k)
August 06 2020 - 6:07AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
August 5, 2020
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X]
|
Form 40-F [ ]
|
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Novo
Nordisk A/S – Share repurchase programme
Bagsværd,
Denmark, 5 August 2020 – On 11 May 2020, Novo Nordisk initiated a share repurchase programme in accordance with
Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated
Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase
programme of up to DKK 17 billion to be executed during a 12-month period beginning 5 February 2020.
Under the programme, initiated 11 May 2020, Novo
Nordisk has repurchased B shares for an amount up to DKK 2.6 billion in the period from 12 May 2020 to 4 August 2020. The programme
is now concluded.
Since the announcement as of 28 July 2020, the following
transactions have been made:
|
Number of
B shares
|
Average
purchase price
|
Transaction
value, DKK
|
Accumulated, last announcement
|
5,359,150
|
|
2,338,027,461
|
28 July 2020
|
103,000
|
428.15
|
44,099,961
|
29 July 2020
|
101,000
|
427.21
|
43,148,533
|
30 July 2020
|
103,000
|
424.48
|
43,720,976
|
31 July 2020
|
103,000
|
420.82
|
43,344,297
|
3 August 2020
|
103,000
|
414.21
|
42,663,250
|
4 August 2020
|
109,810
|
409.76
|
44,995,285
|
Accumulated under the programme
|
5,981,960
|
|
2,599,999,763
|
The details for each
transaction made under the share repurchase programme are published on novonordisk.com.
Page 2 of 2
With the transactions stated above, Novo Nordisk
owns a total of 20,063,980 B shares of DKK 0.20, corresponding to 0.9% of the share capital, as treasury shares. The total amount
of A and B shares in the company is 2,350,000,000 including treasury shares.
Novo Nordisk
expects to repurchase B shares for an amount up to DKK 17 billion during a 12- month period beginning 5 February 2020. As of
4 August 2020, Novo Nordisk has since 5 February 2020 repurchased a total of 20,059,179 B shares at an average share price of
DKK 426.28 per B share equal to a transaction value of DKK 8,550,787,732.
Novo
Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to
defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering
scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs
about 43,100 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq
Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook,
Twitter, LinkedIn, YouTube.
Further information
Media:
|
|
|
Anne Margrethe Hauge
|
+45 4442 3450
|
amhg@novonordisk.com
|
Ken Inchausti (US)
|
+1 609 240 9429
|
kiau@novonordisk.com
|
|
|
|
Investors:
|
|
|
Daniel Muusmann Bohsen
|
+45 3075 2175
|
dabo@novonordisk.com
|
Valdemar Borum Svarrer
|
+45 3079 0301
|
jvls@novonordisk.com
|
Ann Søndermølle Rendbæk
|
+45 3075 2253
|
arnd@novonordisk.com
|
Mark Joseph Root
|
+45 3079 4211
|
mjhr@novonordisk.com
|
Kristoffer Due Berg (US)
|
+1 609 235 2989
|
krdb@novonordisk.com
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
|
|
|
Company announcement No 48 / 2020
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: August 5, 2020
|
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer
|
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Sep 2023 to Sep 2024